Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
AIDS and HIV
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - AIDS and HIV
    Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment - (JAMA)
    TopAbstracts in AIDS and HIV 06/22/2009 - (DGNews)
    TopAbstracts in AIDS and HIV 06/08/2009 - (DGNews)
    Supplementary feeding with either ready-to-use fortified spread or corn-soy blend in wasted adults starting antiretroviral therapy in Malawi: randomised, investigator blinded, controlled trial - (BMJ)
    TopAbstracts in AIDS and HIV 05/25/2009 - (DGNews)

    News archive

     Recent webcasts/CME - AIDS and HIV
  • An Individualized Approach to Selecting Initial Antiretroviral Regimens
  • Strategies for Improving Compliance in Patients on HIV Medications

    Webcasts/CME archive

     Recent cases - AIDS and HIV
      Mesothelioma in an HIV/AIDS Patient Without History of Asbestos Exposure: Possible Role For Immunosuppression in Mesothelioma: A Case Report
      Pulmonary Kaposi Sarcoma in a Human Immunodeficiency Virus - Infected Woman: A Case Report
      Penile Kaposi Sarcoma in an HIV Negative Man: A Case Report
      A Rare Case of Intussusception Leading to the Diagnosis of Acquired Immune Deficiency Syndrome: A Case Report
      HIV-Infection and International Travel: Pretravel Patient Assessment and Management

      Cases archive
        




      my personal edition > aids and hiv > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Efavirenz Superior to Nevirapine for Treating HIV in Coinfected Patients Treated With Rifampin for Tuberculosis: Presented at AIDS 2008

        By Ed Susman

        MEXICO CITY -- August 4, 2008 -- An efavirenz-based regimen appears more successful than a nevirapine-based regimen in the treatment of human immunodeficiency virus (HIV) in patients coinfected with tuberculosis who have already been treated with the antibiotic rifampin, according to researchers speaking here at the 17th International AIDS Conference (AIDS 2008).

        "In our study, virological outcomes [for HIV] were inferior when nevirapine-based antiretroviral therapy was commenced while taking antitubercular treatment," noted study author Andrew Boulle, MB, ChB, Infectious Disease Epidemiology Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. He added, however, that virological outcomes were comparable "when starting efavirenz-based therapy, or when tuberculosis developed while taking established nevirapine-based or efavirenz-based therapies."

        About 16.3% of study patients who initiated nevirapine-based HIV therapy while taking rifampin experienced elevated HIV viral loads within 6 months compared with 8.35% of similar patients who initiated HIV treatment with a regimen that includes efavirenz (P < .001), Dr. Boulle noted here August 3 at a media briefing held by the Journal of the American Medical Association (JAMA). Dr. Boulle's study will appear this week in the HIV/AIDS-themed issue of JAMA on August 6, 2008.

        The study retrospectively followed patients treated in the Cape Town suburb of Khayelitsha from 2001 through 2006. All patients were coinfected with HIV and tuberculosis; 209 patients were treated with nevirapine at a starting dose of 200 mg/day for the first 2 weeks, followed by 200 mg twice daily. These patients were compared with 1,074 patients treated with efavirenz (600 mg/day).

        An additional 1,728 patients on nevirapine who did not have tuberculosis at the time of treatment initiation were compared with 961 patients whose treatment was initiated with efavirenz and were not being treated for tuberculosis.

        The data suggest that if a choice is available between efavirenz and nevirapine -- and the patient is already being treated with rifampin -- then efavirenz would be a better choice, Dr. Boulle concluded. He noted that, in South Africa, where efavirenz is available, most clinicians have adopted that choice. Across most of southern Africa, however, the only current choice for a non-nucleoside reverse transcriptase inhibitor is nevirapine.


        [Presentation title: Outcomes of Nevirapine- and Efavirenz-Based Antiretroviral Therapy When Coadministered With Rifampin-Based Antitubercular Therapy.]




      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send